[ET Net News Agency, 29 October 2021] Shanghai Junshi Biosciences Co., Ltd. (01877)
said the company has received the Acceptance Notice issued by the National Medical
Products Administration. The investigational new drug application for the JS026 injection
has been accepted.
JS026 injection is a recombinant fully human monoclonal antibody, which is mainly used
to prevent and treat the COVID-19. JS026 targets the S1 subunit of the SARS-CoV-2 spike
protein, binding to the receptor binding domain (RBD) with high affinity, blocking the
binding between RBD and the angiotensin converting enzyme 2 (ACE2) in the host cell
surface receptor, thereby further blocking the infection of host cells by SARS-CoV-2. (RC)